Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules

(2021) Beatriz G. de la Torre et al.   MOLECULES

Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development

(2021) Xing Huang et al.   Molecular Cancer

Unlocking the potential of antibody–drug conjugates for cancer therapy

(2021) Joshua Z. Drago et al.   Nature Reviews Clinical Oncology

2020 FDA TIDES (Peptides and Oligonucleotides) Harvest

(2021) Othman Al Musaimi et al.   Pharmaceuticals

Antibody‒drug conjugates: Recent advances in linker chemistry

(2021) Zheng Su et al.   Acta Pharmaceutica Sinica B

Loncastuximab Tesirine: First Approval

(2021) Arnold Lee   DRUGS

Advances and Limitations of Antibody Drug Conjugates for Cancer

(2021) Candice Maria Mckertish et al.   Biomedicines

Tisotumab Vedotin: First Approval

(2021) Anthony Markham   DRUGS

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy

(2021) Juliana T. W. Tong et al.   MOLECULES

Metabolism of bioconjugate therapeutics: why, when, and how?

(2020) Hanlan Liu et al.   DRUG METABOLISM REVIEWS

The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules

(2020) Beatriz G. de la Torre et al.   MOLECULES

Breaking a Couple: Disulfide Reducing Agents

(2020) Sinenhlanhla N. Mthembu et al.   CHEMBIOCHEM

Trastuzumab Deruxtecan: First Approval

(2020) Susan J. Keam   DRUGS

Improving the Stability of Maleimide‐Thiol Conjugation for Drug Targeting

(2020) Marianne Lahnsteiner et al.   CHEMISTRY-A EUROPEAN JOURNAL

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

(2020) Elaine Chang et al.   CLINICAL CANCER RESEARCH

Belantamab Mafodotin: First Approval

(2020) Anthony Markham   DRUGS

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin

(2020) Rohit K Jain et al.   Cancer Management and Research

Antibody–Drug Conjugates: The Last Decade

(2020) Nicolas Joubert et al.   Pharmaceuticals

The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities

(2020) Ashleigh S. Davey et al.   Cancers

Antibody-Drug Conjugate-Based Therapeutics: State of the Science

(2019) Michael J Birrer et al.   JNCI-Journal of the National Cancer Institute

Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index

(2019) Steven Coats et al.   CLINICAL CANCER RESEARCH

From Dyestuff Chemistry to Cancer Theranostics: The Rise of Rylenecarboximides

(2019) Chendong Ji et al.   ACCOUNTS OF CHEMICAL RESEARCH

Antibody–drug conjugates for cancer

(2019) Cindy H Chau et al.   LANCET

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

(2019) Robert J. Kreitman et al.   BLOOD

Antibody-Drug Conjugates: A Comprehensive Review

(2019) Puregmaa Khongorzul et al.   MOLECULAR CANCER RESEARCH

ADCs, as novel revolutionary weapons for providing a step forward in targeted therapy of malignancies

(2019) Nooshafarin Amani et al.   Current Drug Delivery

Targeting death receptors for drug-resistant cancer therapy: Codelivery of pTRAIL and monensin using dual-targeting and stimuli-responsive self-assembling nanocomposites

(2018) Fan Xu et al.   BIOMATERIALS

Phase 1 Trials of anti-ENPP3 antibody drug conjugates in advanced refractory renal cell carcinomas

(2018) John A Thompson et al.   CLINICAL CANCER RESEARCH

An intelligent dual stimuli-responsive photosensitizer delivery system with O 2 -supplying for efficient photodynamic therapy

(2018) Hongjuan Zhao et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer

(2018) Kentaro Tanaka et al.   LUNG CANCER

Antibody Drug Conjugates in Thoracic Malignancies

(2018) Jose M. Pacheco et al.   LUNG CANCER

The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules

(2018) Beatriz de la Torre et al.   MOLECULES

Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design

(2018) Pamela A. Trail et al.   PHARMACOLOGY & THERAPEUTICS

Moxetumomab Pasudotox: First Global Approval

(2018) Sohita Dhillon   DRUGS

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors

(2018) John H. Strickler et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of Ring-Opening Reaction of Succinimide Linkers in ADCs

(2018) Kai Zheng et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification

(2017) Eric Angevin et al.   EUROPEAN JOURNAL OF CANCER

Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates

(2017) Sergii Kolodych et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

(2017) Kathleen N. Moore et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

(2017) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

(2017) Rebecca Suk Heist et al.   JOURNAL OF CLINICAL ONCOLOGY

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

(2017) Charles M Rudin et al.   LANCET ONCOLOGY

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

(2017) Paul J. Carter et al.   NATURE REVIEWS DRUG DISCOVERY

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs

(2016) Jeffrey C. Kern et al.   BIOCONJUGATE CHEMISTRY

Antibody-drug conjugates—an emerging class of cancer treatment

(2016) Nikolaos Diamantis et al.   BRITISH JOURNAL OF CANCER

Antibody-drug conjugates for non-oncological indications

(2016) Renhe Liu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Linkers Having a Crucial Role in Antibody–Drug Conjugates

(2016) Jun Lu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody–Drug Conjugates

(2016) Jeffrey C. Kern et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Recent advances in the construction of antibody–drug conjugates

(2016) Vijay Chudasama et al.   Nature Chemistry

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

(2016) Kyoji Tsuchikama et al.   Protein & Cell

Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis

(2016) Ping Zeng et al.   Scientific Reports

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

(2015) Jessica R. McCombs et al.   AAPS Journal

Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates

(2015) Magdalena Dorywalska et al.   BIOCONJUGATE CHEMISTRY

Antibody-drug conjugates as novel anti-cancer chemotherapeutics

(2015) C. Peters et al.   BIOSCIENCE REPORTS

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

(2015) A. N. Starodub et al.   CLINICAL CANCER RESEARCH

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Craig H Moskowitz et al.   LANCET

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies

(2015) Boris Shor et al.   MOLECULAR IMMUNOLOGY

Antibody–Drug Conjugates (ADCs): Magic Bullets at Last!

(2015) John M. Lambert   MOLECULAR PHARMACEUTICS

GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis

(2015) G Maric et al.   ONCOGENE

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma

(2015) Michael Roth et al.   PEDIATRIC BLOOD & CANCER

Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies

(2015) Inês de Paula Costa Monteiro et al.   PHARMACOGENOMICS

Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy

(2014) Ravi V. J. Chari et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy

(2014) L. Nathan Tumey et al.   BIOCONJUGATE CHEMISTRY

Antibody–drug conjugates—A new wave of cancer drugs

(2014) Hervé Bouchard et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update

(2014) Isabelle Tranoy-Opalinski et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Abstract A73: A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870).

(2014) V. Boni et al.   MOLECULAR CANCER THERAPEUTICS

Crosslinked ionic polysaccharides for stimuli-sensitive drug delivery

(2013) Carmen Alvarez-Lorenzo et al.   ADVANCED DRUG DELIVERY REVIEWS

Effect of HA14-1 on Apoptosis-Regulating Proteins in HeLa Cells

(2013) Kanwal Rehman et al.   Chemical Biology & Drug Design

A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

(2013) V. Ribrag et al.   CLINICAL CANCER RESEARCH

The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia

(2013) H. Carol et al.   CLINICAL CANCER RESEARCH

Antibody–drug conjugates: current status and future directions

(2013) Heidi L. Perez et al.   DRUG DISCOVERY TODAY

Cathepsin B as a cancer target

(2013) Christopher S Gondi et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Monoclonal antibody-based therapies in cancer: Advances and challenges

(2013) Puja Sapra et al.   PHARMACOLOGY & THERAPEUTICS

Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability

(2013) Kirsten Achilles Poon et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer

(2013) J. G. Drachman et al.   Hematology-American Society of Hematology Education Program

Drug-conjugated antibodies for the treatment of cancer

(2012) John M. Lambert   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Antibody-Drug Conjugates for the Treatment of Cancer

(2012) John A. Flygare et al.   Chemical Biology & Drug Design

Disulfide Linkage: A Potent Strategy in Tumor-Targeting Drug Discovery

(2012) J. Wang et al.   CURRENT MEDICINAL CHEMISTRY

The future of antibodies as cancer drugs

(2012) Janice M. Reichert et al.   DRUG DISCOVERY TODAY

Gemtuzumab Ozogamicin: Time to Resurrect?

(2012) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

(2012) Barbara Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody–drug conjugates: Basic concepts, examples and future perspectives

(2012) Giulio Casi et al.   JOURNAL OF CONTROLLED RELEASE

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

(2012) Peter D Senter et al.   NATURE BIOTECHNOLOGY

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage

(2011) Brenda A. Kellogg et al.   BIOCONJUGATE CHEMISTRY

Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin

(2011) A. D. Ricart   CLINICAL CANCER RESEARCH

Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates

(2011) Robert Y. Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Challenges in developing bioanalytical assays for characterization of antibody–drug conjugates

(2011) Jean Philippe Stephan et al.   Bioanalysis

Antibody drug conjugates — Trojan horses in the war on cancer

(2011) U. Iyer et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Combined Hyperthermia and Radiotherapy for the Treatment of Cancer

(2011) Punit Kaur et al.   Cancers

Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP

(2010) John F. DiJoseph et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The role of surgery in the treatment of gastric cancer

(2010) Yingqiang Shi et al.   JOURNAL OF SURGICAL ONCOLOGY

Antibody–drug conjugates for cancer: poised to deliver?

(2010) Bethan Hughes   NATURE REVIEWS DRUG DISCOVERY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents

(2010) Scott C. Jeffrey et al.   ACS Medicinal Chemistry Letters

Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

(2009) Laurent Ducry et al.   BIOCONJUGATE CHEMISTRY

Synthesis and antimicrobial activity of 2-fluorophenyl-4,6-disubstituted [1,3,5]triazines

(2009) Mona Saleh et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma

(2009) Akihiro Takeshita et al.   BRITISH JOURNAL OF HAEMATOLOGY

Potent antibody drug conjugates for cancer therapy

(2009) Peter D Senter   CURRENT OPINION IN CHEMICAL BIOLOGY

Hydrolytic Stability of Hydrazones and Oximes

(2008) Jeet Kalia et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Antibody-Drug Conjugates for Cancer Therapy

(2008) Paul J. Carter et al.   CANCER JOURNAL

A History of Cancer Chemotherapy

(2008) Vincent T. DeVita et al.   CANCER RESEARCH

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

(2007) Ravi V. J. Chari   ACCOUNTS OF CHEMICAL RESEARCH